Comparison of survivor scores for differentiation therapy of cancer to those for checkpoint inhibition: Half full or half empty

Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors

(2018) Kristian M. Hargadon et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism

(2018) Dina Stroopinsky et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

(2018) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer

(2018) Nicholas Borcherding et al.   JOURNAL OF MOLECULAR BIOLOGY

The Dualistic Origin of Human Tumors

(2018) Jinsong Liu   SEMINARS IN CANCER BIOLOGY

NKG2D and Its Ligands: “One for All, All for One”

(2018) Alessandra Zingoni et al.   Frontiers in Immunology

Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC).

(2018) Luis G. Paz-Ares et al.   JOURNAL OF CLINICAL ONCOLOGY

24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

(2018) Hossein Borghaei et al.   Journal of Thoracic Oncology

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy

(2018) Yiyi Yan et al.   Frontiers in Immunology

NKG2D Ligands–Critical Targets for Cancer Immune Escape and Therapy

(2018) Dominik Schmiedel et al.   Frontiers in Immunology

Immunotherapy 2.0: Improving the Response to Checkpoint Inhibitors

(2018) M.J. Friedrich   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

(2017) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

(2017) David P. Carbone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

(2017) Richard M. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

(2017) Hashem O. Alsaab et al.   Frontiers in Pharmacology

Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities

(2016) KM Morrissey et al.   CTS-Clinical and Translational Science

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

(2016) J.M. Michot et al.   EUROPEAN JOURNAL OF CANCER

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

(2016) Corey J Langer et al.   LANCET ONCOLOGY

Cocktails for cancer with a measure of immunotherapy

(2016) Heidi Ledford   NATURE

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

(2016) Paul T. Nghiem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab for Patients with Relapse after Allogeneic Transplantation

(2016) Matthew S. Davids et al.   NEW ENGLAND JOURNAL OF MEDICINE

Regulatory Role of IL-1R8 in Immunity and Disease

(2016) Martina Molgora et al.   Frontiers in Immunology

Neuroblastoma

(2016) Katherine K. Matthay et al.   Nature Reviews Disease Primers

Acute myeloid leukemia-Major progress over four decades and glimpses into the future

(2015) Hagop Kantarjian   AMERICAN JOURNAL OF HEMATOLOGY

Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States

(2015) Martin Tallman et al.   Clinical Lymphoma Myeloma & Leukemia

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

EZH2 as a potential target in cancer therapy

(2014) Michael T McCabe et al.   Epigenomics

The CD40/CD40L system: A new therapeutic target for disease

(2013) Bikui Zhang et al.   IMMUNOLOGY LETTERS

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

(2011) Y. Shen et al.   BLOOD

Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor

(2011) M. S. Redell et al.   BLOOD

The PD-1 pathway in tolerance and autoimmunity

(2010) Loise M. Francisco et al.   IMMUNOLOGICAL REVIEWS

A practical guide to understanding Kaplan-Meier curves

(2010) Jason T. Rich et al.   OTOLARYNGOLOGY-HEAD AND NECK SURGERY

Molecular mechanism and function of CD40/CD40L engagement in the immune system

(2009) Raul Elgueta et al.   IMMUNOLOGICAL REVIEWS

Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study

(2009) Katherine K. Matthay et al.   JOURNAL OF CLINICAL ONCOLOGY